News

Subscribe to our biannual newsletter and never miss the lastest updates.

 

EraCal featured among Switzerland's promising startups

9. September 2020

EraCal selected to the top100 Swiss StartUps for the first time in 2020. Thank you for all your support.

Nature and Merck KGaA highlight EraCal’s effort towards a long-term obesity therapy

30. June 2020

Thank you for depicting the advantages of EraCal’s phenotypic platform to identify selective and potent appetite suppressors. We are honored to be selected as a Spinoff prize finalist.

EraCal is a member of the Swiss National Startup Team 2020

22. April 2020

The Swiss Life Science National Team selected EraCal for its 2020 class. Thank you for recognizing our entrepreneurial ambitions.

IMD and EraCal join forces

13. December 2019

EraCal selected as an entrepreneurial showcase for IMD‘s Executive MBA class 2020.

EraCal closed oversubscribed seed round

16. October 2019

EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.

EraCal in the news of the University of Zurich

10. September 2019

The UZH news (English Deutsch) tells our initial StartUp journey towards a new therapeutic solution for obesity.

EraCal wins MIT life science angels award

28. August 2019

EraCal won the MIT life science angels award and enjoyed thrilling days in Boston. Thank you for recognizing our creative science strategy and our global mission!

EraCal received first investment

1. June 2019

The Life Sciences Fund (50% Novartis Venture Fund, 50% UZH Foundation) kicks of EraCal’s lead optimization program. Thank you for joining us on this important mission!

EraCal is a »venture» finalist

16. May 2019

EraCal Therapeutics is among the top 10 in the “Health & Nutrition” vertical of the  »venture» business plan competition 2019. »venture» is Switzerland’s leading startup contest for entrepreneurs with high-tech business ideas.

EraCal moves to Schlieren

1. April 2019

EraCal moves to the IncubatorLab at Wagisstrasse 12 in Schlieren, Zurich, one of the best European biotechnology research hubs.

EraCal wins venturekick

31. January 2019

The venturekick jury selected EraCal Therapeutics Ltd. as a top Swiss start-up. Thank you very much for your continuing support of our vision!

EraCal in the scientific news

31. October 2018

Articles in Science Advance and the news of the University of Zurich (English Deutsch) describe part of our drug discovery strategy and its power for translational research.

 
 

Disclaimer ¦ Contact ¦ Newsletter ¦ ©2020 by EraCal Therapeutics Ltd.